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Direct evidence that hydralazine can induce hypoxia in both transplanted
and spontaneous murine tumours
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Summary Hydralazine can substantially decrease blood flow and increase hypoxia in transplanted tumours.
Previous indirect studies have suggested that hydralazine does not induce such effects in spontaneous tumours.
We have now directly investigated the ability of hydralazine to increase hypoxia in both transplanted and
spontaneous murine tumours by measuring tumour oxygen partial pressure (P02) distributions using an
Eppendorf oxygen electrode. Spontaneous tumours arose at different sites in CDF1 mice, while transplanted
tumours were produced by implanting a C3H mouse mammary carcinoma on the backs of the same mouse
strain. Measurements of P02 were made in anaesthetised mice immediately before and 45min after an
intravenous injection of 5 mg kg_, hydralazine. In the transplanted tumours hydralazine significantly
decreased tumour oxygenation, such that the percentage of P02 values < 5 mmHg increased from 45% to
87%, and median P02 decreased from 5 to 3 mmHg. Similar significant changes were induced by hydralazine
in the spontaneous tumours, the percentage of p02 values < 5 mmHg increasing from 60% to 94% while the
median P02 values decreased from 8 to 2 mmHg. These results clearly show that there is no difference in the
response of transplanted and spontaneous mouse tumours to hydralazine.
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It has been well established that the antihypertensive drug
hydralazine (Sutton, 1986), when injected into animals at
high doses, can substantially decrease blood flow to a variety
of transplanted tumours (Voorhees and Babbs, 1982; Chaplin
and Acker, 1987; Horsman et al., 1989, 1992; Bhujwalla et
al., 1990; Kalmus et al., 1990; Lin and Song, 1990; Fisker et
al., 1991; Honess and Bleehen, 1992; Dewhirst et al., 1994).
This effect leads to changes in tumour oxygenation (Stratford
et al., 1987; Horsman et al., 1989; Lin and Song, 1990; Fisker
et al., 1991; Lemmon and Brown, 1991) and energy
metabolism (Okunieff et al., 1988; Bhujwalla et al., 1990;
Tozer et al., 1990; Bremner et al., 1991), and as a result this
drug will enhance the anti-tumour activity of a range of
agents. These include hypoxic cell cytotoxins such as
bioreductive drugs (Chaplin and Acker, 1987; Bremner et al.,
1990) and hyperthermia (Horsman et al., 1989; Kalmus et al.,
1990), as well as certain conventional chemotherapeutic
agents such as melphalan (Stratford et al., 1987; Adams et
al., 1989; Chaplin et al., 1989) and chlorambucil (Skarsgard
et al., 1992).
However, recent studies using 31P magnetic resonance spec-
troscopy (31P-MRS) reported that primary or spontaneous
murine tumours were in general unresponsive to hydralazine
(Field et al., 1991; Wood et al., 1992). Moreover, when one
of the unresponsive primary tumours was subcutaneously
transplanted into the flanks of isogeneic mice it did respond
to hydralazine (Field et al., 1991). These findings have not
only raised questions about the potential adjuvant use of
vascular modifying agents such as hydralazine in clinical
therapy, they have also led to criticism about the use of
transplanted murine tumours as preclinical screens for testing
the activity of such agents.
We have now used an Eppendorf oxygen electrode to
measure directly tumour oxygenation, both before and after
hydralazine treatment, in a transplanted C3H mouse mam-
mary carcinoma and a series of spontaneous murine
tumours. Our results show that hydralazine can in fact




A C3H mouse mammary carcinoma was used. Its derivation
and maintenance have been described previously (Overgaard,
1980). Experimental tumours were produced following sterile
dissection of large flank tumours. Macroscopically viable
tumour tissue was minced with a pair of scissors and 5-10 lL
of this material injected subcutaneously on the backs of 10-
14-week old male and female C3D2Fl/Bom (C3H/Tif
female x DBA/2 male) mice. Measurements of tumour
oxygenation were carried out when tumours had achieved
volumes ranging from about 500 to 5000 mm3 (see Table I),
tumour size being determined by the formula DI x D2
x D3 x n/6 (where the D values represent three orthogonal
diameters). This size range was selected to allow direct com-
parison with our spontaneous tumours.
Spontaneous tumours
The characteristics of the spontaneous mouse tumours are
also listed in Table I. Tumours were used when they had
reached about 500-5000mm3 in size. These volumes were
chosen because they were similar to the range of spontaneous
tumour volumes used in previous 31P-MRS studies (Field et
al., 1991). Our spontaneous tumours were not deliberately
produced for these experiments but arose at different sites in
male and female C3D2Fl/Bom mice aged between 14 and 28
months that had previously undergone some form of radia-
tion treatment at around 3 months of age in connection with
other experiments. Two mice had received whole body
irradiation with 6-8 Gy given in three daily fractions. The
remaining eight mice had been implanted with a C3H mam-
mary carcinoma in the right rear foot and then locally
irradiated with 30-70 Gy when the tumours were < 200
mm3. Determination of the tumour type was made from
microscopic examination of haematoxylin-stained histological
sections. DNA index of the tumours was estimated by flow
cytometry on ethanol-fixed tumour specimens as described
previously (Barlogie et al., 1977).
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Table 1 Characteristics of the transplanted and spontaneous mouse tumours
Transplanted Transplanted
(Controls)a (HDZ treated)a Spontaneous (HDZ treated)a
Tumour Tumour Tumour Mouse
Mouse size Mouse size Mouse size Mouse Tumour Tumour Radiation' age DNA
No. (mm3) sex (mm3) sex (mM3) sex type site treatment (months) index
1 509 F 509 F 507 F Malignant lymphoma Left flank Foot 22 1.00
2 749 F 1056 M 545 M Sarcoma Head at right eye Whole body 20 1.89
3 919 M 1144 M 848 F Necrotic tissue Right side of neck Foot 22 NA
4 968 F 1257 M 973 M Adenocarcinoma Right breast Whole body 14 2.37
5 968 M 1290 F 1131 F Adenocarcinoma Anal-genital region Foot 24 1.00
6 1021 F 1469 F 1851 F NA Anal-genital region Foot 23 NA
7 2547 F 1736 F 2118 F Adenocarcinoma Top of right foreleg Foot 22 1.00
8 2681 F 2136 F 2706 F Adenocarcinoma Left flank Foot 28 1.00
9 2893 F 2545 F 2786 F Adenocarcinoma Left shoulder Foot 22 NA
10 5012 M 4976 F 4838 F Anaplastic tumour Right flank Foot 22 1.00
aMicewereintravenously injectedwitheithersaline(controls) orhydralazine(HDZ; 5 mg kg-).bMicehadpreviously beenirradiatedwhenaround
3 months old. Radiation wasgiveneitherwholebody(6-8 Gyinthreefractions), orlocallytotherightrearfoot(singledoseof30-70 Gy)inwhich a
C3H mammary carcinoma had been implanted. NA, not available.
Drugpreparation
Hydralazine (1-hydrazinophthalazine) was supplied by Ciba-
Geigy, Copenhagen, Denmark. A fresh solution was pre-
pared in sajine (0.9% sodium chloride) before each series of
measurements. It was then injected intravenously (i.v.) at a
constant injection volume of 0.02 ml g-' mouse body weight.
PO2 measurements
Measurements of tumour P02 were made using a com-
puterised fine-needle polarographic oxygen electrode probe
(Eppendorf, Hamburg, Germany), the details of which have
been described previously (Kallinowski et al., 1990). The
location of some of the spontaneous tumours required the
use of an anaesthetic, thus for consistency p02 measurements
in all the spontaneous and transplanted tumours were per-
formed under anaesthesia. To achieve this mice were given a
single injection with a mixture of hypnorm (fluanisonum
10mgml' + fentanyl 0.2mgml'), diazepam (5 mgml-')
and water in the ratio of 1:1:4. This mixture was injected
intraperitoneally at 0.005 ml g-' mouse body weight. The
oxygen electrode was then inserted up to a depth of 1 mm
into the tumour. It was subsequently moved automatically
through the tissue in 0.7 mm increments, followed each time
by a 0.3 mm backward step before measurement. Between
two and six repeated parallel insertions were performed in
each tumour. Mice were then injected with saline or hyd-
ralazine and 45 min later the P02 measurements were
repeated, the animals remaining anaesthetised for this entire
period. The average number ofp02 values obtained per set of
measurements was 120 (range 37-220). Body temperature
was monitored using a rectally inserted thermocouple before
hydralazine injection and at various times after, and main-
tained at the prehydralazine level by warming the mice from
above with a standard desk-top lamp.
Data analysis
The relative frequency of the P02 measurements was autom-
atically calculated and displayed as a histogram, but from the
original raw data a number of parameters can be selected to
reflect tumour oxygenation. In this study we decided to show
the results from only two of these end points, namely,
median P02 and percentage of P02 values < 5 mmHg,
because the former is indicative of the overall oxygenation
status, while the latter is likely to include all the radio-
biologically hypoxic cells in the tumour. Statistical analysis of
the data was performed using the Student t-test after testing
for variance homogeneity by an F-test, with P = 0.05 selected
as the level of significance.
Results
Histological characterisation of the spontaneous tumours
showed that half of them were adenocarcinomas (Table I).
The remainder being a malignant lymphoma, a sarcoma, an
anaplastic tumour and one tumour (mouse number 3) which
histologically was actually found to consist of highly vas-
cularised, yet necrotic tissue, with no malignant cells being
seen. Seven of the tumours also had their DNA-index deter-
mined and of these, five were diploid (DNA index of 1.00),
while the remaining two were either hypotetraploid (mouse
number 2) or hypertetraploid (mouse number 4). The trans-
planted C3H mouse mammary carcinoma was found to be
tetraploid with a DNA index of 2.01.
Figures 1 and 2 show the median P02 and percentage of
p02 values < 5 mmHg, before and after drug injection, for all
the transplanted and spontaneous tumours used in this study.
To check on the validity of making repeated P02 measure-
ments in tumours, measurements were made in transplanted
tumours before and after injection with saline. The pretreat-
ment median P02 values ranged from 2 to 8 mmHg
(mean= 5 mmHg) and the percentage of P02 values
< 5 mmHg ranged from 8% to 94% (mean = 55%). Follow-
ing injection with saline the p02 measurements were repeated
and although there was some variability between the pre- and
post-saline measurements, there were no consistent changes.
Moreover, the post-injection results covered a similar range
(median values went from 2 to 9 mmHg and the percen-
tage < 5 mmHg from 19% to 99%) as the presaline
measurements, and the average estimates of the median P02
values and percentage of P02 values < 5 mmHg were cal-
culated to be 5 mmHg and 58% respectively, which were not
significantly different from the average presaline values.
The pretreatment p02 values measured in the transplanted
tumours used for the hydralazine study were almost identical
to those seen in the saline-treated transplanted tumours.
However, when mice were injected with hydralazine every
single transplanted tumour became less well oxygenated.
Indeed, for all ten tumours the average of the median p02
values was decreased from 5 to 3 mmHg, while the percen-
tage of p02 values < 5 mmHg increased from 45% to 87%,
and these changes in both parameters were significant.
Similar significant changes were also seen for mean p02 and
the percentage of values < 10 mmHg, but not for the percen-
tage < 2.5 mmHg (data not shown).
For the spontaneous tumours the prehydralazine treatment
P02 values did appear to show a wider range, at least in
terms of median P02, than the pretreatment values measured
in transplanted tumours, however, the average results for all
ten spontaneous tumours were not significantly different from
the average pretreatment p02 estimates of the transplanted













Figure 1 The effect of hydralazine (5 mgkg-1) on the oxygenation status of transplanted C3H mouse mammary carcinomas and
spontaneous murine tumours. Measurements ofpO2 were made in tumours before (-, 0) or 45 min after (+, *) an i.v. injection
with saline or hydralazine (HDZ). Results show the median P02 values obtained either in individual tumours (top panels) or the















Figure 2 The effect of hydralazine (5 mg kg-') on the oxygenation status of transplanted C3H mouse mammary carcinomas and
spontaneous murine tumours. Measurements ofPO2 were made in tumours before (-, 0) or 45 min after (+, 0) an i.v. injection
with saline or hydralazine (HDZ). Results show the percentage ofP02 values < 5 mmHg obtained either in individual tumours (top
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tumour showed a decreased oxygenation status. For the
median p02 the average value for all ten tumours decreased
from 8 to 2 mmHg, while the percentage of P02
values < 5 mmHg increased from 60% to 94%, and again
these changes were significant. The average estimates for the
mean PO2 and the percentage of values < 2.5 and 10 mmHg
also showed significant differences between the pre- and post-
hydralazine treatments (data not shown).
Discussion
It has been established that the Eppendorf oxygen electrode
can directly measure the oxygenation status of both animal
and human tumours (Kallinowski et al., 1990; Hoeckel et al.,
1993; Horsman et al., 1995). Using this electrode we have
now demonstrated that a large single dose of hydralazine
(5 mg kg-') can significantly decrease the level of oxygena-
tion in a transplanted C3H mouse mammary carcinoma.
These changes were identical to those we reported for hyd-
ralazine in small 200mm3 C3H tumours (Horsman et al.,
1995) and are consistent with our radiation studies in this
tumour, which showed that for several hours after hyd-
ralazine injection tumour response to radiation was equiva-
lent to that seen in tumours made fully radiobiologically
hypoxic by clamping (Horsman et al., 1989; Fisker et al.,
1991), an effect that correlated with the drug's ability to
decrease tumour blood flow. Studies with other transplanted
tumour models have also shown that hydralazine can
decrease tumour blood flow (Voorhees and Babbs, 1982;
Chaplin and Acker, 1987; Bhujwalla et al., 1990; Kalmus et
al., 1990; Lin & Song, 1990; Honess and Bleehen, 1992;
Dewhirst et al., 1994) and oxygenation (Stratford et al., 1987;
Lin and Song, 1990; Lemmon and Brown, 1991).
Our current study also investigated the effect of hyd-
ralazine on the oxygenation status of ten spontaneous murine
tumours and in every case a reduction in tumour oxygena-
tion was observed. These tumours arose in mice that had
either been whole-body irradiated some 11 to 17 months
earlier, or in animals which 19-25 months before had been
implanted in the right rear foot with the C3H mammary
carcinoma and the tumour then controlled by local irradia-
tion. Histological examination and measurement of DNA-
index clearly showed that these spontaneous tumours were
not recurrences of the previously transplanted tumour.
Moreover, although some of the tumours may have been
induced by the previous radiation treatment, the time at
which the spontaneous tumours appeared and the site of
growth, suggests that the irradiation was probably not res-
ponsible for all the tumours. Two other studies have looked
at the effect of hydralazine in primary or spontaneous
tumours, both using 3MP-MRS to assess response. One found
that 12/19 primary tumours did not respond to hydralazine
(Field et al., 1991), while the other showed that 10/12 spon-
taneous tumours failed to respond to the drug (Wood et al.,
1992). Why there should be this apparent discrepancy
between theP02 and 31P-MRS data is not clear. The study by
Field et al. (1991) used radiation- or chemically induced
primary tumours and there is evidence showing that murine
tumours that can respond to hydralazine do not do so if
grown in a previously irradiated site (Lemmon and Brown,
1991). While this may help explain the lack of effect in some
of the primary tumours in the Field study, and why a
non-responding primary tumour did respond when trans-
planted, it probably does not explain the failure to see an
effect in all the primary tumours, nor does it account for the
lack of effect in the majority of truly spontaneous tumours in
the study by Wood et al. (1992). OurPO2 measurements also
showed that for at least four out of ten of the spontaneous
tumours the percentage ofP02 values < 5 mmHg before hyd-
ralazine treatment were around 80% or above. Such tumours
could be considered very hypoxic and, although they did
respond to hydralazine, they were incapable of showing any
large change. Although 3'P-MRS can be used to monitor
changes in tumour metabolism with growth or after treat-
ment (Rofstad et al., 1988; Adams et al., 1992), its ability to
actually measure the level of hypoxia in tumours is limited
(Rofstad et al., 1988; Nordsmark et al., 1995). It is, therefore,
possible that the failure to see a response in spontaneous
tumours with 3'P-MRS after hydralazine may have been
because these tumours were relatively hypoxic and unable to
respond. However, this again is unlikely to be the explana-
tion for the lack of effect with so many tumours in the
3"P-MRS studies; even in our experiments some 60% of the
spontaneous tumours could be considered reasonably well
oxygenated. Nor does it explain why hydralazine-induced
changes in metabolic activity can be detected with 3'P-MRS
in transplanted tumours (Okunieff et al., 1988; Bhujwalla et
al., 1990; Tozer et al., 1990; Bremner et al., 1991). Clearly
there is no easy explanation as to why our current study
showed substantial effects of hydralazine in spontaneous
tumours using measurements Of PO2 as the end point, and
other studies using 3"P-MRS failed to find such effects.
Nevertheless, the important finding from our current study
is that all the spontaneous tumours we studied responded to
hydralazine and the average effect was identical to that seen
in size-matched, transplanted murine tumours. Whether or
not hydralazine can actually be used clinically to decrease
blood flow in human tumours and thus enhance the anti-
tumour activity of hypoxic cell cytotoxins is not clear.
Limited clinical data has shown that hydralazine can
decrease blood flow in a glioblastoma (Chaplin and Trotter,
1991) and a squamous cell carcinoma (Acker et al., 1987),
but actually increased flow by 38% in lung tumours (Rowell
et al., 1990). That latter effect was seen with a drug dose that
produced only an 8% decrease in mean arterial blood pres-
sure (Rowell and Clark 1990). Experimental murine studies
have also reported hydralazine-induced increases in tumour
blood flow of around 30% (Kalmus et al., 1990; Horsman et
al., 1992), but these occurred at low drug doses and, as in the
human lung studies, were associated with a small decrease in
mouse blood pressure of about 10%. Only when blood pres-
sure was reduced by 15% or more did blood flow drop below
control levels (Horsman et al., 1992). It seems unlikely that
such large decreases in blood pressure can be routinely
achieved in humans, although decreases in excess of 20%
were observed in the glioblastoma and squamous cell car-
cinoma studies (B Acker, written communication, January
1991). What is needed are agents that can physiologically
decrease tumour blood flow without substantially decreasing
blood pressure. Our finding that transplanted and spon-
taneous tumours responded identically to hydralazine sug-
gests that transplanted tumours grown in mice would be a
good effective screen to identify such agents.
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